Trap: Confusing 'genetically modified (GM)' crops with 'genome-edited' crops. GM involves inserting foreign DNA (transgenic). Genome editing (CRISPR, TALEN) modifies the plant's own genes without foreign DNA. India regulates both differently — GM under Rules 1989; genome editing under the 'SDN 1, 2, 3' framework.
Most confused: The difference between Bt cotton (approved for commercial cultivation in India since 2002) and Bt brinjal (approved but never commercially released due to a moratorium imposed by then Environment Minister Jairam Ramesh in 2010). Also, GM mustard (DMH-11) was approved for environmental release in 2022 but is not yet cultivated.
Key anchor: Indian biotechnology is regulated by multiple bodies — the Department of Biotechnology (DBT — policy), the Genetic Engineering Appraisal Committee (GEAC — approvals under Environment Protection Act), the Drugs Controller General of India (DCGI — pharmaceutical approvals), and the Institutional Biosafety Committees (IBSC — local oversight).
Current affairs hook: DMH-11 (GM mustard) commercial release debate (2022-26); India's genome-edited crop policy (Guidelines 2022 — exempting SDN-1 and SDN-2 from GM regulations); the bioeconomy target of $300 billion by 2030; the WHO pandemic treaty and India's vaccine manufacturing capacity.
Mains hinge: Biotechnology questions should connect the 'triple helix' model of innovation — government (DBT, BIRAC), academia (IITs, IISc, TIFR), and industry (Biocon, Serum Institute). Show how India's strength in vaccines (world's largest vaccine manufacturer) positions it as a global biotech player but also attracts ethical scrutiny.
Core Concept
Biotechnology in India spans vaccine manufacturing (where India is a global powerhouse), agricultural biotechnology (where debate and regulation have created a cautious path), and emerging areas like gene therapy and synthetic biology. India's bioeconomy has grown from $10 billion (2014) to over $130 billion (2025), with a target of $300 billion by 2030. The sector is a key pillar of the 'Make in India' and 'Atmanirbhar Bharat' initiatives.
Healthcare Biotechnology: Vaccines and Beyond
India is the 'pharmacy of the world', producing 60% of the world's vaccines and supplying 20-30% of generic medicines globally. The COVID-19 pandemic showcased this capability:
Covaxin: India's first indigenous COVID-19 vaccine, developed by Bharat Biotech in collaboration with ICMR. An inactivated whole-virion vaccine (traditional platform), it was granted emergency use authorisation in January 2021.
ZyCoV-D: The world's first plasmid DNA vaccine, developed by Zydus Cadila. It is needle-free (administered via a three-dose regimen using a PharmaJet injector) and the first DNA vaccine approved for human use anywhere.
Covishield: Manufactured by Serum Institute of India under licence from Oxford-AstraZeneca. SII produced over 2 billion doses, making it the largest vaccine manufacturer by volume.
India's vaccine success is built on decades of capacity building through the DBT, the National Institute of Virology (Pune), and the Serum Institute. The National Biopharma Mission (2017-2022) and the 'Make in India' production-linked incentive (PLI) scheme for pharmaceuticals have strengthened the ecosystem.
Beyond vaccines, India has developed indigenous: (a) diagnostic kits for TB, HIV, Hepatitis B/C; (b) stem cell therapies (the National Centre for Stem Cell Sciences, Bengaluru); (c) gene therapy trials for sickle cell disease (in collaboration with the US NIH); and (d) CAR-T cell therapy (NexCAR19, India's first indigenously developed CAR-T therapy for cancer, approved in 2024).
Agricultural Biotechnology: The GM Story
India's agricultural biotechnology journey has been marked by cautious progress and intense debate.
(1) Bt Cotton: The only GM crop approved for commercial cultivation in India. Approved in 2002, it covers over 95% of India's cotton area (120 lakh hectares). Bt cotton has increased yields (from 300 kg/hectare in 2001 to 500 kg/hectare in 2020) and reduced pesticide use. However, it has also been criticised for high seed costs, pest resistance (pink bollworm developed resistance by 2015), and farmer suicides in some states.
(2) Bt Brinjal: Approved by GEAC in 2009 for commercial release but an indefinite moratorium was imposed by the Environment Minister in 2010. No GM food crop has been commercially released in India to date.
(3) GM Mustard (DMH-11): Developed by the Delhi University's Centre for Genetic Manipulation of Crop Plants, DMH-11 uses the 'barnase-barstar' system for hybrid seed production (not insect resistance). The GEAC approved its environmental release in October 2022. The Supreme Court has stayed the release, hearing petitions against GM mustard. The government has argued that GM mustard can reduce India's edible oil import bill (60% of India's edible oil is imported).
(4) Genome Editing Policy (2022): The DBT released 'Guidelines for Safety Assessment of Genome-Edited Plants' in 2022, exempting SDN-1 and SDN-2 genome edits (site-directed nucleases that make precise changes without inserting foreign DNA) from the GM regulatory framework. This is a significant policy shift that could accelerate the development of drought-resistant, pest-resistant, and nutritionally enhanced crops.
(5) GM Maize and Rice: Both are in the research pipeline. The Indian Agricultural Research Institute (IARI) has developed biofortified crops (zinc-rich rice, iron-rich pearl millet) through conventional breeding, but GM approaches are also being pursued.
The Regulatory Framework
India's biotechnology regulation is complex and multi-layered:
Department of Biotechnology (DBT): The nodal ministry for biotech policy and research funding.
BIRAC (Biotechnology Industry Research Assistance Council, 2012): A DBT interface agency that funds startups and industry-academia collaborations. Has supported over 2,000 startups.
Genetic Engineering Appraisal Committee (GEAC): The apex body under the Ministry of Environment, Forest and Climate Change (MoEFCC) for evaluating and approving GM crops under the Environment Protection Act 1986 and the Rules 1989 (Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells).
Institutional Biosafety Committees (IBSCs): Local-level oversight at research institutions.
Review Committee on Genetic Manipulation (RCGM): Under the DBT, reviews research proposals.
The 1989 Rules are widely considered outdated and the government is working on the 'Biotechnology Regulatory Authority of India' (BRAI) Bill to create a standalone regulator, but the Bill has lapsed multiple times.
Ethical Concerns
(1) GM Food Safety: Critics argue that GM foods have not been tested for long-term human health effects. The DMH-17 (GM mustard) approval was challenged on grounds of incomplete allergenicity and toxicity data. The government's position is that GEAC approvals follow internationally accepted safety protocols (Codex Alimentarius, WHO/FAO guidelines).
(2) Gene Patents: The patenting of genes and living organisms (the US Supreme Court's Myriad Genetics case, 2013) has implications for India's patent regime (Section 3(j) of the Indian Patents Act, 1970 — plants and animals in whole or any part thereof are not inventions and are not patentable). India's position is that naturally occurring genes cannot be patented, but synthetic genes and processes can be.
(3) CRISPR Ethics: The use of CRISPR-Cas9 for human germline editing (heritable changes) is banned in India, consistent with the global moratorium. The ICMR and DBT have issued guidelines (the 'National Guidelines for Stem Cell Research' and the soon-to-be finalised 'CRISPR Ethics Guidelines') restricting research to somatic cell editing (non-heritable).
(4) Biopiracy and Benefit Sharing: India has traditional knowledge about medicinal plants and genetic resources. The Biological Diversity Act 2002 and the Nagoya Protocol (2014, to which India is a signatory) regulate access to genetic resources and ensure benefit sharing with local communities.
(5) Clinical Trial Ethics: India reformed its clinical trial regulations after the 2012-13 controversies (allegations of unethical trials on tribals in Gujarat). The Drugs and Clinical Trials Rules 2019 strengthened informed consent, compensation for trial-related injury, and post-trial access.
Bioeconomy and Future
India's bioeconomy is driven by four sectors: biopharma (60% of the sector), bio-services (20%), bio-agri (15%), and bio-industrial (5%). The BioE3 Policy (Biotechnology for Economy, Environment and Employment, 2024) focuses on 'green biotech' — using biotechnology for sustainable manufacturing, waste-to-value products, and bio-based alternatives to plastics.
The National Biotechnology Development Strategy (2021-25) and the upcoming 'BioIndia 2030' roadmap target $300 billion bioeconomy by 2030, 5,000 biotech startups, and 100 bio-incubators.
Key Facts
India's bioeconomy: ~$130 billion (2025); target $300 billion by 2030
Vaccine production: 60% of global vaccines; Serum Institute is world's largest manufacturer by volume
Biological Diversity Act: 2002 (access and benefit sharing)
BioE3 Policy: 2024 (Biotechnology for Economy, Environment and Employment)
Biotech startups: ~6,500 (2025); target 10,000 by 2030
Previous Year Questions
Year
Stage
What was tested
2024
Prelims
What is 'ZyCoV-D'? World's first plasmid DNA vaccine.
2023
Mains
Discuss the ethical concerns associated with genetically modified crops. Should India approve GM mustard?
2022
Prelims
'BIRAC' is an organisation under which ministry? Department of Biotechnology.
2021
Mains
How has India's biotechnology sector responded to the COVID-19 pandemic? Critically examine.
2020
Prelims
Which committee approved GM mustard for environmental release? GEAC.
2019
Mains
What are the regulatory hurdles in India's biotechnology sector? Suggest reforms.
2018
Prelims
'Bt toxin' is produced by which bacteria? Bacillus thuringiensis.
Statement Elimination Guide
Correct: "Bt cotton is the only genetically modified crop approved for commercial cultivation in India. GM mustard (DMH-11) has been approved for environmental release but not commercial cultivation."
False: "India does not produce any GM food crops." (Correct — no GM food crop has been commercially released. Bt brinjal was approved but never released due to a moratorium. But saying 'India does not produce' is accurate as of 2026.)
Trap: "Genome editing and genetic modification are the same under Indian regulations." (False. The 2022 DBT guidelines exempt SDN-1 and SDN-2 genome editing from the GM regulatory framework.)
Correct: "The Biological Diversity Act 2002 regulates access to genetic resources and ensures fair and equitable benefit sharing with local communities."
False: "India allows CRISPR-based human germline editing." (India follows the global moratorium — only somatic cell editing is permitted under strict ICMR/DBT guidelines.)
Current Affairs Hook
In 2026, the GM mustard (DMH-11) case remains pending before the Supreme Court. The government has submitted its affidavit supporting commercial release, citing the edible oil import burden (₹1.4 lakh crore annually). The DBT has issued updated guidelines for CRISPR research in agriculture, allowing field trials of genome-edited crops without requiring GEAC approval (SDN-1/SDN-2 category). India's first CAR-T cell therapy, NexCAR19 (developed by ImmunoACT, IIT Bombay), has been commercialised at a fraction of global cost ($60,000 per treatment vs $400,000+ abroad). The BioE3 Policy has launched five 'Green Biotech Missions' focusing on bio-based plastics, industrial enzymes, and sustainable protein. India has committed to the WHO's '100 Days Mission' for developing pandemic vaccines within 100 days of the next pandemic.
Agriculture (GS 3): GM crops, biofortification, sustainable agriculture; input costs and farmer income; IPR in seeds (the 'seed bill' debate).
Health (GS 2): Vaccine manufacturing, drug pricing, clinical trials, WHO-GMP standards.
Environment (GS 3): Biodiversity, biopiracy, Biosafety Protocol (Cartagena Protocol — India is a signatory).
Ethics (GS 4): Gene patents, human germline editing, clinical trial ethics, access to medicines. *Polity (GS 2)**: Regulatory framework (BRAI Bill), Centre-state relations on GM crop approvals (some states have banned GM crops despite GEAC approval).
Common Mistakes
"Bt cotton is a food crop": Bt cotton is a commercial fibre crop, not a food crop. Its seeds produce cotton; the leaves are not consumed by humans. This distinction matters for food safety debates.
"GM mustard (DMH-11) is insect-resistant like Bt cotton": DMH-11 uses the barnase-barstar system for hybrid seed production, not for pest resistance. It is a 'hybridisation technology' GM, not a 'pest resistance' GM.
"The BR (Biotechnology Regulatory) Authority Bill has been passed": The BRAI Bill has lapsed several times. India still regulates biotechnology under the 1989 Rules, which are outdated.
"CRISPR can cure all genetic diseases": CRISPR is a powerful tool for gene editing but has off-target effects, delivery challenges, and ethical constraints. It is not yet approved for therapeutic use in India.
"India's clinical trial rules are the most stringent in the world": The 2019 Rules are comprehensive, but critics argue they have made India less attractive for global clinical trials. The number of clinical trials registered in India declined significantly after the 2013 reforms.
Revision Snapshot
India's biotechnology sector ($130 billion bioeconomy, target $300 billion by 2030) spans healthcare (60% vaccines, Covaxin, ZyCoV-D, CAR-T), agriculture (Bt cotton only commercial GM crop; DMH-17 mustard approved for environmental release but stayed by SC; genome-edited crops exempted from GM Rules via 2022 DBT guidelines), and emerging areas (BioE3 Policy, green biotech). Regulation: DBT (policy), GEAC (GM approvals under EP Act 1986/Rules 1989), BIRAC (startup funding), DCGI (pharma approvals). Ethics: GM food safety debate, gene patents (Indian law prohibits patenting naturally occurring genes), CRISPR germline editing ban, biopiracy and benefit sharing (Biodiversity Act 2002). Key strength: vaccine manufacturing capacity (world's largest). Key challenge: regulatory bottleneck (BRAI Bill pending).
Source Notes
DBT — Annual Report 2024-25, National Biotechnology Development Strategy
BIRAC — Biotech Startup Ecosystem Report 2025
GEAC — Minutes of 2022 Meeting on DMH-17 Environmental Release
ICMR — National Guidelines for Gene Therapy Research (2024)
DBT — Guidelines for Safety Assessment of Genome-Edited Plants (2022)
Ministry of Environment — Biological Diversity Act 2002 and Rules
DCGI — Drugs and Clinical Trials Rules 2019
BioE3 Policy (Biotechnology for Economy, Environment and Employment) — 2024
WHO — Global Vaccine Market Report 2025 (India edition)